Recombinant Human PVRIG Protein, His Tag, 100 µg

Background
Human PVRIG (poliovirus receptor related immunoglobulin domain-containing protein), also known as CD112 receptor (CD112R), is an approximately 34 kDa single transmembrane protein in the poliovirus receptor-like protein (PVR) family. The CD112R gene encodes a putative single transmembrane protein, which is composed of a single extracellular IgV domain, one transmembrane domain, and a long intracellular domain. Notably, the intracellular domain of phatases. The extracellular domain sequence of human and mouse CD112R have 65.3% similarity. CD112R may act as a coinhibitory receptor that suppresses T-cell receptor-mediated signals.

Source
Recombinant Human PVRIG, His Tag (PVG-H52H4) is expressed from human 293 cells (HEK293). It contains AA Thr 41 - Asp 171 (Accession # Q6DKI7-1).
Predicted N-terminus: Thr 41

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 15.6 kDa. The protein migrates as 20-30 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.
 
Purity
>90% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Structural basis for the immune recognition and selectivity of the immune receptor PVRIG for ligand Nectin-2"
Hu, Han, Wang et al
Structure (2024)
(2) "PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways"
Yang, Wang, Byrnes et al
Cancer Immunol Res (2024)
(3) "Characterization of a novel anti-PVRIG antibody with Fc-competent function that exerts strong antitumor effects via NK activation in preclinical models"
Xue, Zhang, Li et al
Cancer Immunol Immunother (2024) 73 (5), 81
Showing 1-3 of 33 papers.